US20080193552A1 - Topical medicament for skin injuries and disorders - Google Patents
Topical medicament for skin injuries and disorders Download PDFInfo
- Publication number
- US20080193552A1 US20080193552A1 US12/103,597 US10359708A US2008193552A1 US 20080193552 A1 US20080193552 A1 US 20080193552A1 US 10359708 A US10359708 A US 10359708A US 2008193552 A1 US2008193552 A1 US 2008193552A1
- Authority
- US
- United States
- Prior art keywords
- oil
- topical product
- topical
- product according
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000699 topical effect Effects 0.000 title claims description 25
- 239000003814 drug Substances 0.000 title description 28
- 208000028990 Skin injury Diseases 0.000 title description 2
- 208000017520 skin disease Diseases 0.000 title description 2
- 229940025703 topical product Drugs 0.000 claims abstract description 34
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 239000003026 cod liver oil Substances 0.000 claims abstract description 14
- 235000012716 cod liver oil Nutrition 0.000 claims abstract description 14
- 235000019486 Sunflower oil Nutrition 0.000 claims abstract description 12
- 239000004359 castor oil Substances 0.000 claims abstract description 12
- 235000019438 castor oil Nutrition 0.000 claims abstract description 12
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 12
- 239000004006 olive oil Substances 0.000 claims abstract description 12
- 235000008390 olive oil Nutrition 0.000 claims abstract description 12
- 239000002600 sunflower oil Substances 0.000 claims abstract description 12
- 235000019489 Almond oil Nutrition 0.000 claims abstract description 11
- 239000008168 almond oil Substances 0.000 claims abstract description 11
- 230000006378 damage Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003974 emollient agent Substances 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 235000019198 oils Nutrition 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- 235000019155 vitamin A Nutrition 0.000 claims description 10
- 239000011719 vitamin A Substances 0.000 claims description 10
- 235000019166 vitamin D Nutrition 0.000 claims description 10
- 239000011710 vitamin D Substances 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 235000013871 bee wax Nutrition 0.000 claims description 8
- 239000012166 beeswax Substances 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 6
- 229930003316 Vitamin D Natural products 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 235000019271 petrolatum Nutrition 0.000 claims description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 229940045997 vitamin a Drugs 0.000 claims description 6
- 229940046008 vitamin d Drugs 0.000 claims description 6
- 230000002745 absorbent Effects 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 abstract description 5
- 238000005299 abrasion Methods 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 26
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 208000014674 injury Diseases 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- 239000003925 fat Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 241000256844 Apis mellifera Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- -1 i.e. Substances 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000276457 Gadidae Species 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940022150 morrhuic acid Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003043 other dermatological preparations in atc Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention relates to an all-natural product for topical application to the skin.
- the present invention relates to a product which may be formulated as a topical medicament for treating a wide variety of skin injuries and disorders, or as a topical product for cosmetic use.
- a topical medicament which possesses high therapeutic efficacy and which is based upon natural ingredients would be highly desirable.
- the present invention provides a topical medicament for the treatment of a wide variety of injuries to, and disorders of, the skin and various mucosal surfaces.
- the medicament comprises, as its primary ingredient, an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, castor oil and virgin wax.
- This oleaginous base can be combined with excipients commonly used in the preparation of topically-applied medicaments or cosmetic agents.
- compositions according to the present invention contain from about 10 to about 50 percent by weight of virgin wax (yellow beeswax), based on the total weight of the formulation.
- Preferred compositions also contain Vitamins A, D and E, which can be provided from natural oleaginous sources or as synthetic additives
- skin is meant to refer to the epidermis and dermis, as well as mucosal membranes.
- the present invention provides a topical medicament useful for the treatment of burns and other injuries to and disorders of the skin and mucosal surfaces of the body, including those injuries that result in the loss of epidermal and dermal substance.
- “Mucosal surfaces” as used herein includes the mucosal surfaces of the vaginal area and anal area, as well as the buccal and nasal mucosal surfaces.
- the medicament comprises yellow beeswax (also known as “virgin wax”) preferably in an oleaginous base that is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body.
- the oleaginous base is a mixture of vegetable and animal oils which, when combined in certain proportions, have been found to provide a topical medicament that leads to rapid healing.
- the topical medicament of the invention has been found to reduce exudate formation and edema and to help clear skin wounds of necrotic tissue and purulent secretions, thus encouraging the appearance of granulation tissue and re-epithelization.
- the medicament also possesses anti-inflammatory, analgesic, antibacterial, hemostatic and emollient properties.
- the product does not adhere to wounds.
- the present invention provides a topical product in which the oleaginous base comprises olive oil, sunflower oil, almond oil, cod liver oil and castor oil. Beeswax is combined with this base and an excipient which is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body, so as to provide, for example, a cream, gel, lotion or ointment.
- the excipient provides emollient properties.
- Olive oil, almond oil, and castor oil are anhydrous vegetable oils made up of liquid or acid, fatty or saturated triglycerides.
- Olive oil is obtained from the ripe fruit of Olea europaea and its crop varieties.
- Sunflower oil is obtained from the seed/fruit of Helianthus annus, and is known to contain about 75 mg Vitamin E (mixed tocopherols) per 100 g.
- Almond oil is obtained from the seeds of Prunus amygdalus.
- Cod liver oil is the oil obtained from the fresh livers of Gadus morrhua and other species of Gadidae. The oil is extracted from the liver using steam, which breaks down the cellular membranes. Once obtained it is frozen and filtered to separate the stearin. Cod liver oil contains predominantly glycerides with non-saturated fatty acids that together comprise morrhuic acid. It also contains cholesterol, but the most important constituents are vitamins A and D, i.e., retinol and cholecalciferol or vitamin D 3 . Cod liver oil is known to contain at least about 850 U.S.P. units (255 ⁇ g) of Vitamin A per gram, and at least about 85 U.S.P. units (2.125 ⁇ g) of Vitamin D per gram.
- Castor oil is the cold-drawn oil of the seeds, stripped of the episperm, of Ricinus communis and other members of its family Euphorbisceae. It is a slightly yellow to colorless thick, viscous liquid with mild odor or odorless and subtle taste.
- the term “virgin wax” or “yellow beeswax” refers to the product of fusion and purification of the honeycomb of the Apis mellifera (Apidae) bee after the honey has been separated.
- the topical medicament contains between about 10 and about 50 percent by weight of yellow beeswax, more preferably between about 18 and about 27 percent, and even more preferably between about 23 and about 25 percent. Concentrations greater than about 50 percent by weight generally are not preferred because of the solid consistency of beeswax resulting in an undesirably high viscosity or hardness of the final product. Percentages are expressed throughout this application as percent by weight, based upon the total weight of the product, unless otherwise noted.
- the topical medicament contains Vitamins A, D and E. Synthetic versions of these vitamins can be added during formulation, or, preferably, the vitamins can be added via the inclusion of their natural sources, for example, cod liver oil and sunflower oil. The amounts of these vitamins can be varied, as can their sources.
- Preferred formulations of the medicaments can contain, per 100 g of the final formulation, between about 1275 and about 3825 ⁇ g Vitamin A, preferably about 2550 ⁇ g; between about 10.625 and about 31.875 ⁇ g Vitamin D, preferably about 21.25; and between about 975 and about 3000 mg Vitamin E, preferably about 2025 mg.
- the excipients used in the topical medicament of the present invention are comprised primarily of emollients.
- Emollients are lipids or substances with a similar consistency which, when applied to the skin, protect and soften the skin, making it more supple.
- Emollients are used primarily as the excipients and bases of ointments and other dermatological preparations.
- a simple classification of emollients is cl as follows:
- Emollients 1 Oil-based Hydrocarbons E.g.: for Animal fats Petroleum ointments Jelly Vegetable eg: Castor oil oils Peanut oil Waxes e.g.: sperm oil 2) Absorbent Cholesterol bases Lanolin Cetyl alcohol Stearyl alcohol 3) Emulsive Sulfated bases alcohols Synthetic surface- active agents Acid soaps Basic soaps e.g.: Stearic acid 4) Water- e.g. soluble Glycerine bases 1) Oil-based: Oil-based emollients include fats. These products are anhydrous, do not absorb water and are insoluble in it, and are non-washable.
- Oil-based emollients include: a) hydrocarbons or mineral fats obtained by the distillation of petroleum (petroleum jelly); b) vegetable oils and liquid triglycerides; c) animal fats or solid natural triglycerides.
- Absorbent bases These bases are anhydrous and insoluble in water, and are hydrophilic. They typically form water-like emulsions in oil and, thus, can incorporate substances in aqueous solutions. In addition, they are largely non-washable.
- Absorbent bases include: a) Lanolin or wool fats that are obtained from sheep's wool and made up of fatty acids and cholesterol esters; and b) cetyl and stearyl alcohols, which are solid alcohols obtained by hydrogenation of their respective acids.
- Emulsive bases These bases absorb water, but are insoluble in it, forming water emulsions in oil that are not very washable and can be easily removed from the skin. They include surface active agents (surfactants) which improve wetting of surfaces. They include: a) soaps or salts of fatty acids that may be acidic or basic depending on whether the lipophilic group is anionic or cationic; b) sulfated alcohols which are semi-synthetic substances; and c) synthetic surface active agents. 4) Water soluble bases: These bases are anhydrous, absorb water, and are completely soluble in water. They are also non-fatty and washable. For example, glycerine is obtained from fats and, due to its hydrophobicity, has the property of extracting water from the surface of the mucosa or denuded skin. It does not damage intact skin.
- these substances When applied to the skin, these substances, which are in general chemically inert, have a protective and emollient action.
- the protective action occurs on healthy and diseased skin and prevents the effects of chemical, mechanical, and physical (cold, wind) irritants while decreasing burning and pruritus and producing an anti-inflammatory effect. Since these substances form a more or less impermeable layer over the skin, they prevent drying of the epidermis over the stratum corneum by decreasing the evaporation of water from the cutaneous surface. Thus, the skin is softer and more supple. In this way, emollients mimic the natural sebaceous layer that covers normal skin.
- the bases envisioned for use in the present invention including the water soluble ones, are well absorbed by the skin, but almost not at all by the epidermis or the sebaceous glands of the hair follicles.
- the excipient is comprised of stearic acid and liquid petroleum jelly, with butylhydroxytoluene (BHT) as a preservative and, optionally, herbal essence.
- BHT butylhydroxytoluene
- Other excipients can be used in lieu of petroleum jelly, such as olive oil, cod liver oil and other natural oils, depending upon the ultimate consistency that is desired which, in turn, depends upon the ultimate use to which the product will be put.
- other preservatives can be substituted for or used in combination with BHT.
- Stearic acid is a mixture of solid fatty acids in variable proportions. It is an absorbent, anhydrous, and non-water soluble base which forms water-type emulsions in oil. When combined with the oil bases, stearic acid increases their consistency (viscosity) and makes them hydrophilic.
- herbal essence refers to any of the well-known extracts of aromatic plants, such as an aromatic extract of chamomile.
- the topical product of the instant invention which can be in the form of, for example, a cream or an ointment, can be formulated as products specifically adapted for a variety of applications including skin, vaginal, and proctological creams/ointments. Regardless of the specific formulation and the environment in which the product is utilized, the topical product of the invention shows ability to stimulate granulation and re-epithelization and to act as an anti-pruritic surface analgesic and anti-inflammatory agent.
- the medicament when in the form of a skin cream or ointment, is preferably spread on a gauze compress to be placed on the effected zone, following which a soft occlusive bandage is applied.
- the go compress When placed over the injury, the go compress should extend beyond the injury, for example by about two-thirds of a centimeter. This regimen is repeated about 3 times daily at the beginning of treatment and then less frequently as a favorable course of treatment is observed. The total time of treatment depends upon how rapidly the healing process progresses. In minor household burns, however, as well as in sunburn, the topical medicament of the invention can be applied directly to the affected skin.
- the topical medicament of the invention is administered using a variety of disposable vaginal and proctological applicators as are well known.
- the quantity of the medicament to be applied should be adapted to the extent of the injury. For maximum benefit, the injury should be thoroughly covered by the medicament.
- the topical medicament of the invention should be stored in a cool place to maximize its preservation.
- the final product can be packaged in, for example, 20 g. and 50 g. tubes, or in 50 g., 100 g., 200 g. and 500 g. jars.
- the present invention is. f-f-rther described in the following Example, which is provided for illustrative purposes only and is not to be construed as limiting.
- the total quantities of the stearic acid and virgin wax are placed in a stainless steel receptacle outfitted with a double casing.
- the ingredients are heated to 65° C.-70° C. so that the solids melt.
- the melted mass is mixed and the total quantity of castor oil, olive oil, cod liver oil, almond oil, and sunflower oil is added to the mixture.
- liquid petroleum jelly or other medically acceptable excipient
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
Abstract
A topical product for the application to the skin or mucosal surfaces comprises yellow beeswax in an oleaginous base of, e.g., olive oil, sunflower oil, almond oil, cod liver oil, castor oil, along with an excipient vehicle. The product is useful in connection with a variety of conditions and ailments of the skin (including burns and abrasions) and mucosal surfaces of, for example, the vaginal and anal areas.
Description
- This application is a continuation-in-part of application Ser. No. 08/623,970 filed Mar. 29, 1996 which is related to provisional application Ser. No. 60/008,122, filed Oct. 30, 1995.
- The present invention relates to an all-natural product for topical application to the skin. In particular, the present invention relates to a product which may be formulated as a topical medicament for treating a wide variety of skin injuries and disorders, or as a topical product for cosmetic use.
- Burns and other injuries to the skin in which there is capillary obstruction or destruction frequently results in scab formation. Elimination of the scab gives way to a bloody surface where healing accompanied by the formation of granulation tissue occurs. The damaged surface is then re-covered by cells that grow from the periphery towards the center of the injured area, in a process of convergent re-epithelization.
- Depending on the location of an injury to the skin, varying degrees of scar retraction can occur. Also, as necrotic tissue, heat, and moisture provide optimal conditions for bacterial growth, when the epidermis is disrupted a bacterial infection can ensue.
- Infections caused by bacteria represent the primary factor retarding the normal process of skin re-epithelization. Therefore, in most cases using conventional treatment the timely application of a skin graft is an advisable option for preventing cutaneous sequelae and to ensure healing within an appropriate time frame. Currently available synthetic materials can be used as a palliative measure for graftable injuries.
- While today it is increasingly possible to successfully combat pain and bacterial infections associated with injuries to the skin, re-epithelization of the injury is critical factor that must be considered in treating these injuries. In deep burns with destruction of the epidermis and/or the dermis, re-epithelization begins along the edges of the injury and in the other dispersed tegumentary organs. This process is slow and granulation tissue forms in excess prior to the re-covering of the epithelium. Therefore, if not treated as soon as possible with skin grafts, these injuries typically contract, often resulting in the formation of deforming and incapacitating scars.
- Improvements in the treatment of burns and other injuries to the skin continue to be sought. A topical medicament which possesses high therapeutic efficacy and which is based upon natural ingredients would be highly desirable.
- The present invention provides a topical medicament for the treatment of a wide variety of injuries to, and disorders of, the skin and various mucosal surfaces. The medicament comprises, as its primary ingredient, an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, castor oil and virgin wax. This oleaginous base can be combined with excipients commonly used in the preparation of topically-applied medicaments or cosmetic agents.
- Preferred compositions according to the present invention contain from about 10 to about 50 percent by weight of virgin wax (yellow beeswax), based on the total weight of the formulation. Preferred compositions also contain Vitamins A, D and E, which can be provided from natural oleaginous sources or as synthetic additives
- Additional features and advantages of the invention will be set forth in the description which follows and will be apparent from the description or may be learned by practice of the invention. For the purposes of this invention, the term “skin” is meant to refer to the epidermis and dermis, as well as mucosal membranes.
- Reference will now be made in detail to the presently preferred embodiments of the invention. The present invention provides a topical medicament useful for the treatment of burns and other injuries to and disorders of the skin and mucosal surfaces of the body, including those injuries that result in the loss of epidermal and dermal substance. “Mucosal surfaces” as used herein includes the mucosal surfaces of the vaginal area and anal area, as well as the buccal and nasal mucosal surfaces. The medicament comprises yellow beeswax (also known as “virgin wax”) preferably in an oleaginous base that is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body. Preferably, the oleaginous base is a mixture of vegetable and animal oils which, when combined in certain proportions, have been found to provide a topical medicament that leads to rapid healing. The topical medicament of the invention has been found to reduce exudate formation and edema and to help clear skin wounds of necrotic tissue and purulent secretions, thus encouraging the appearance of granulation tissue and re-epithelization. The medicament also possesses anti-inflammatory, analgesic, antibacterial, hemostatic and emollient properties. Advantageously, the product does not adhere to wounds.
- In a preferred embodiment, the present invention provides a topical product in which the oleaginous base comprises olive oil, sunflower oil, almond oil, cod liver oil and castor oil. Beeswax is combined with this base and an excipient which is pharmaceutically acceptable for topical application to the skin and/or mucosal surfaces of the human body, so as to provide, for example, a cream, gel, lotion or ointment. Preferably, the excipient provides emollient properties.
- Olive oil, almond oil, and castor oil are anhydrous vegetable oils made up of liquid or acid, fatty or saturated triglycerides. Olive oil is obtained from the ripe fruit of Olea europaea and its crop varieties. Sunflower oil is obtained from the seed/fruit of Helianthus annus, and is known to contain about 75 mg Vitamin E (mixed tocopherols) per 100 g. Almond oil is obtained from the seeds of Prunus amygdalus.
- Cod liver oil is the oil obtained from the fresh livers of Gadus morrhua and other species of Gadidae. The oil is extracted from the liver using steam, which breaks down the cellular membranes. Once obtained it is frozen and filtered to separate the stearin. Cod liver oil contains predominantly glycerides with non-saturated fatty acids that together comprise morrhuic acid. It also contains cholesterol, but the most important constituents are vitamins A and D, i.e., retinol and cholecalciferol or vitamin D3. Cod liver oil is known to contain at least about 850 U.S.P. units (255 μg) of Vitamin A per gram, and at least about 85 U.S.P. units (2.125 μg) of Vitamin D per gram.
- Castor oil is the cold-drawn oil of the seeds, stripped of the episperm, of Ricinus communis and other members of its family Euphorbisceae. It is a slightly yellow to colorless thick, viscous liquid with mild odor or odorless and subtle taste.
- As used herein the term “virgin wax” or “yellow beeswax” refers to the product of fusion and purification of the honeycomb of the Apis mellifera (Apidae) bee after the honey has been separated. Preferably, the topical medicament contains between about 10 and about 50 percent by weight of yellow beeswax, more preferably between about 18 and about 27 percent, and even more preferably between about 23 and about 25 percent. Concentrations greater than about 50 percent by weight generally are not preferred because of the solid consistency of beeswax resulting in an undesirably high viscosity or hardness of the final product. Percentages are expressed throughout this application as percent by weight, based upon the total weight of the product, unless otherwise noted.
- Advantageously, the topical medicament contains Vitamins A, D and E. Synthetic versions of these vitamins can be added during formulation, or, preferably, the vitamins can be added via the inclusion of their natural sources, for example, cod liver oil and sunflower oil. The amounts of these vitamins can be varied, as can their sources. Preferred formulations of the medicaments can contain, per 100 g of the final formulation, between about 1275 and about 3825 μg Vitamin A, preferably about 2550 μg; between about 10.625 and about 31.875 μg Vitamin D, preferably about 21.25; and between about 975 and about 3000 mg Vitamin E, preferably about 2025 mg.
- The excipients used in the topical medicament of the present invention are comprised primarily of emollients. Emollients are lipids or substances with a similar consistency which, when applied to the skin, protect and soften the skin, making it more supple. Emollients are used primarily as the excipients and bases of ointments and other dermatological preparations. A simple classification of emollients is cl as follows:
-
Emollients 1) Oil-based Hydrocarbons E.g.: for Animal fats Petroleum ointments Jelly Vegetable eg: Castor oil oils Peanut oil Waxes e.g.: sperm oil 2) Absorbent Cholesterol bases Lanolin Cetyl alcohol Stearyl alcohol 3) Emulsive Sulfated bases alcohols Synthetic surface- active agents Acid soaps Basic soaps e.g.: Stearic acid 4) Water- e.g. soluble Glycerine bases 1) Oil-based: Oil-based emollients include fats. These products are anhydrous, do not absorb water and are insoluble in it, and are non-washable. Oil-based emollients include: a) hydrocarbons or mineral fats obtained by the distillation of petroleum (petroleum jelly); b) vegetable oils and liquid triglycerides; c) animal fats or solid natural triglycerides. 2) Absorbent bases: These bases are anhydrous and insoluble in water, and are hydrophilic. They typically form water-like emulsions in oil and, thus, can incorporate substances in aqueous solutions. In addition, they are largely non-washable. Absorbent bases include: a) Lanolin or wool fats that are obtained from sheep's wool and made up of fatty acids and cholesterol esters; and b) cetyl and stearyl alcohols, which are solid alcohols obtained by hydrogenation of their respective acids. 3) Emulsive bases: These bases absorb water, but are insoluble in it, forming water emulsions in oil that are not very washable and can be easily removed from the skin. They include surface active agents (surfactants) which improve wetting of surfaces. They include: a) soaps or salts of fatty acids that may be acidic or basic depending on whether the lipophilic group is anionic or cationic; b) sulfated alcohols which are semi-synthetic substances; and c) synthetic surface active agents. 4) Water soluble bases: These bases are anhydrous, absorb water, and are completely soluble in water. They are also non-fatty and washable. For example, glycerine is obtained from fats and, due to its hydrophobicity, has the property of extracting water from the surface of the mucosa or denuded skin. It does not damage intact skin. - When applied to the skin, these substances, which are in general chemically inert, have a protective and emollient action. The protective action occurs on healthy and diseased skin and prevents the effects of chemical, mechanical, and physical (cold, wind) irritants while decreasing burning and pruritus and producing an anti-inflammatory effect. Since these substances form a more or less impermeable layer over the skin, they prevent drying of the epidermis over the stratum corneum by decreasing the evaporation of water from the cutaneous surface. Thus, the skin is softer and more supple. In this way, emollients mimic the natural sebaceous layer that covers normal skin. The bases envisioned for use in the present invention, including the water soluble ones, are well absorbed by the skin, but almost not at all by the epidermis or the sebaceous glands of the hair follicles.
- In practicing the present invention, preferably the excipient is comprised of stearic acid and liquid petroleum jelly, with butylhydroxytoluene (BHT) as a preservative and, optionally, herbal essence. Other excipients can be used in lieu of petroleum jelly, such as olive oil, cod liver oil and other natural oils, depending upon the ultimate consistency that is desired which, in turn, depends upon the ultimate use to which the product will be put. Additionally, other preservatives can be substituted for or used in combination with BHT.
- Stearic acid is a mixture of solid fatty acids in variable proportions. It is an absorbent, anhydrous, and non-water soluble base which forms water-type emulsions in oil. When combined with the oil bases, stearic acid increases their consistency (viscosity) and makes them hydrophilic. As used herein, the term herbal essence refers to any of the well-known extracts of aromatic plants, such as an aromatic extract of chamomile.
- The topical product of the instant invention, which can be in the form of, for example, a cream or an ointment, can be formulated as products specifically adapted for a variety of applications including skin, vaginal, and proctological creams/ointments. Regardless of the specific formulation and the environment in which the product is utilized, the topical product of the invention shows ability to stimulate granulation and re-epithelization and to act as an anti-pruritic surface analgesic and anti-inflammatory agent.
- In treating a subject with a the topical medicament of the present invention, including subjects with venous diseases and ulcerations, the medicament, when in the form of a skin cream or ointment, is preferably spread on a gauze compress to be placed on the effected zone, following which a soft occlusive bandage is applied. When placed over the injury, the go compress should extend beyond the injury, for example by about two-thirds of a centimeter. This regimen is repeated about 3 times daily at the beginning of treatment and then less frequently as a favorable course of treatment is observed. The total time of treatment depends upon how rapidly the healing process progresses. In minor household burns, however, as well as in sunburn, the topical medicament of the invention can be applied directly to the affected skin. When treating gynecologic and proctologic conditions, preferably the topical medicament of the invention is administered using a variety of disposable vaginal and proctological applicators as are well known.
- In light of the fact that the medicament is applied in a topical fashion, it is not typical to set maximum and minimum doses. Rather, the quantity of the medicament to be applied should be adapted to the extent of the injury. For maximum benefit, the injury should be thoroughly covered by the medicament.
- Very little, if any, of the components of medicament are absorbed by the skin or mucosal surface; Thus, no side effects associated with the use of the topical medicament of the invention are expected. In addition, since the contents of the topical medicament are natural substances, the medicament of the invention is well tolerated locally and systemically.
- Once prepared, the topical medicament of the invention should be stored in a cool place to maximize its preservation. The final product can be packaged in, for example, 20 g. and 50 g. tubes, or in 50 g., 100 g., 200 g. and 500 g. jars.
- The present invention is. f-f-rther described in the following Example, which is provided for illustrative purposes only and is not to be construed as limiting.
- In order to prepare a 100 g. sample of the topical medicament of the invention, the following ingredients were combined:
-
PRIMARY INGREDIENTS Olive oil 5.72 g Sunflower oil 21.72 g Almond oil 21.72 g Cod liver oil 10.72 g Castor oil 3.72 g Virgin wax 23.40 g EXCIPIENT BASE Stearic acid 2.0 g Herbal essence 0.980 g Butylhydroxytoluene 0.020 g Liquid petroleum jelly 10.0 g - The total quantities of the stearic acid and virgin wax are placed in a stainless steel receptacle outfitted with a double casing. The ingredients are heated to 65° C.-70° C. so that the solids melt.
- The melted mass is mixed and the total quantity of castor oil, olive oil, cod liver oil, almond oil, and sunflower oil is added to the mixture.
- The total quantity of butylhydroxytoluene is dissolved in the herbal essence and added to the mixture from step 2.
- The total quantity of liquid petroleum jelly (or other medically acceptable excipient) is added and the mixture is mixed for 30 minutes while maintaining the heat and, then, cooling slowly with continuous shaking.
Claims (26)
1. A topical product for application to the skin or mucosal surface, comprising an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, castor oil and beeswax, and a phamaceutically-acceptable excipient for topical application to the skin.
2. A topical product for application to the skin or mucosal surface, comprising about 5% olive oil, about 21% sunflower oil, about 21% almond oil, about 10% cod liver oil, about 3% castor oil and about 23% beeswax, the balance of said product comprising a phamaceutically-acceptable excipient for topical application to the skin.
3. A topical product for application to the skin comprising between about 10 and about 50 percent by weight of beeswax, a pharmaceutically-acceptable emollient for topical application to the skin and a pharmaceutically-acceptable excipient for topical application to the skin.
4. The topical product according to claim 3 , comprising between about 18 and about 27 percent by weight of beeswax.
5. The topical product according to claim 3 , comprising between about 23 and about 25 percent by weight of beeswax.
6. The topical product according to claim 3 , further comprising Vitamin A.
7. The topical product according to claim 3 , further comprising Vitamin D.
8. The topical product according to claim 3 , further comprising Vitamin E.
9. The topical product according to claim 3 , further comprising Vitamins A, D and E.
10. The topical product according to claim 3 , further comprising, per 100 g of the topical product, between about 1275 and about 3825 μg Vitamin A.
11. The topical product according to claim 10 , further comprising about 2550 μg Vitamin A per 100 g of the topical product.
12. The topical product according to claim 3 , further comprising, per 100 g of the topical product, between about 10.625 and about 31.875 μg Vitamin D.
13. The topical product according to claim 12 , comprising, per 100 g of the topical product, about 21.25 μg Vitamin D.
14. The topical product according to claim 3 , further comprising, per 100 g of the topical product, between about 975 and about 3000 mg Vitamin E.
15. The topical product according to claim 14 , comprising, per 100 g of the topical product, about 2025 mg Vitamin E.
16. The topical product according to claim 3 , wherein the emollient comprises olive oil, almond oil and/or castor oil.
17. The topical product according to claim 3 , wherein the excipient comprises liquid petroleum jelly.
18. The topical product according to claim 17 , wherein the excipient further comprises stearic acid.
19. The topical product according to claim 3 , further comprising cod liver oil.
20. The topical product according to claim 3 , further comprising sunflower oil.
21. The topical product according to claim 20 , further comprising sunflower oil.
22. The topical product according to claim 3 , further comprising a preservative.
23. The topical product according to claim 22 , wherein said preservative is butylhydroxytoluene.
24. A composition for application to the skin or mucosal surface to treat bums and other injuries comprising:
(a) from about 18 to about 27 percent by weight of beeswax;
(b) an oleaginous base of olive oil, sunflower oil, almond oil, cod liver oil, and castor oil; and
(c) one or more emollients selected from the group consisting of:
oil-based emollients;
absorbent bases;
emulsive bases; and
water-soluble bases,
wherein the composition contains between about 1275 and about 3825 μg of Vitamin A.
25. The composition of claim 24 , wherein the composition contains between about 10.625 and about 31.875 μg of Vitamin D.
26. The composition of claim 24 , wherein the composition contains between about 975 and about 3000 mg of Vitamin E.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/103,597 US20080193552A1 (en) | 1995-10-30 | 2008-04-15 | Topical medicament for skin injuries and disorders |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US812295P | 1995-10-30 | 1995-10-30 | |
| US62397096A | 1996-03-29 | 1996-03-29 | |
| US23183799A | 1999-01-15 | 1999-01-15 | |
| US09/810,660 US7357923B1 (en) | 1995-10-30 | 2001-03-19 | Topical medicament for skin injuries and disorders |
| US12/103,597 US20080193552A1 (en) | 1995-10-30 | 2008-04-15 | Topical medicament for skin injuries and disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/810,660 Continuation US7357923B1 (en) | 1995-10-30 | 2001-03-19 | Topical medicament for skin injuries and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20080193552A1 true US20080193552A1 (en) | 2008-08-14 |
Family
ID=39281559
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/810,660 Expired - Fee Related US7357923B1 (en) | 1995-10-30 | 2001-03-19 | Topical medicament for skin injuries and disorders |
| US12/103,597 Abandoned US20080193552A1 (en) | 1995-10-30 | 2008-04-15 | Topical medicament for skin injuries and disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/810,660 Expired - Fee Related US7357923B1 (en) | 1995-10-30 | 2001-03-19 | Topical medicament for skin injuries and disorders |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US7357923B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10016466B2 (en) * | 2014-11-17 | 2018-07-10 | Rev Pharma Corp | Topical medicament for skin and mucosal injuries associated with Epidermolisis bullosa |
| WO2020188305A1 (en) * | 2019-03-18 | 2020-09-24 | Patsianidi Helen | Ointment for the treatment of burns |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470880B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Methods of reducing hair loss and/or facilitating hair growth and/or regrowth |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3431340A (en) * | 1967-10-19 | 1969-03-04 | John Otto George | Medicinal preparation for the treatment of burns and other traumatic wounds |
| US3825563A (en) * | 1969-10-01 | 1974-07-23 | G Ahrens | Production of stable,nonhydrous,homogeneous,in natural and mineral oils soluble vitamin-e-active cream-base-co-esters of the mineral-oil-insoluble d-alpha-tocopheryl-acid-succinate with anhydrous oils |
| US4695452A (en) * | 1984-10-10 | 1987-09-22 | Gannis Peter M | Cosmetic stick |
| US5466457A (en) * | 1993-03-01 | 1995-11-14 | Beiersdorf Aktiengesellschaft | Cosmetic sticks |
| US5874479A (en) * | 1991-03-01 | 1999-02-23 | Warner-Lambert Company | Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same |
| US6099866A (en) * | 1986-01-31 | 2000-08-08 | Slimak; K. M. | Compositions for topical application and other products from fresh beeswaxes |
| US7479291B1 (en) * | 2007-11-07 | 2009-01-20 | Janice D Baltimore | Hair product |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2041594A5 (en) * | 1969-04-30 | 1971-01-29 | Expanscience | |
| US5047232A (en) * | 1986-09-29 | 1991-09-10 | Schering-Plough Healthcare Products, Inc. | Non-aqueous waterproof oil-based compositions and method of preparing same |
| US5503825A (en) * | 1994-01-10 | 1996-04-02 | Lane; Barry | Lip balm composition |
| US5597849A (en) * | 1994-11-14 | 1997-01-28 | Medical Polymer Technologies, Inc. | Stick formulations for topical drug delivery of therapeutic agents and uses thereof |
-
2001
- 2001-03-19 US US09/810,660 patent/US7357923B1/en not_active Expired - Fee Related
-
2008
- 2008-04-15 US US12/103,597 patent/US20080193552A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3431340A (en) * | 1967-10-19 | 1969-03-04 | John Otto George | Medicinal preparation for the treatment of burns and other traumatic wounds |
| US3825563A (en) * | 1969-10-01 | 1974-07-23 | G Ahrens | Production of stable,nonhydrous,homogeneous,in natural and mineral oils soluble vitamin-e-active cream-base-co-esters of the mineral-oil-insoluble d-alpha-tocopheryl-acid-succinate with anhydrous oils |
| US4695452A (en) * | 1984-10-10 | 1987-09-22 | Gannis Peter M | Cosmetic stick |
| US6099866A (en) * | 1986-01-31 | 2000-08-08 | Slimak; K. M. | Compositions for topical application and other products from fresh beeswaxes |
| US5874479A (en) * | 1991-03-01 | 1999-02-23 | Warner-Lambert Company | Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same |
| US5466457A (en) * | 1993-03-01 | 1995-11-14 | Beiersdorf Aktiengesellschaft | Cosmetic sticks |
| US7479291B1 (en) * | 2007-11-07 | 2009-01-20 | Janice D Baltimore | Hair product |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10016466B2 (en) * | 2014-11-17 | 2018-07-10 | Rev Pharma Corp | Topical medicament for skin and mucosal injuries associated with Epidermolisis bullosa |
| US10426803B2 (en) | 2014-11-17 | 2019-10-01 | Rev Pharma Corp | Topical medicament for skin and mucosal injuries |
| US10596205B2 (en) | 2014-11-17 | 2020-03-24 | REV PHARMA Corp. | Topical medicament for skin and mucosal injuries |
| WO2020188305A1 (en) * | 2019-03-18 | 2020-09-24 | Patsianidi Helen | Ointment for the treatment of burns |
Also Published As
| Publication number | Publication date |
|---|---|
| US7357923B1 (en) | 2008-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rai et al. | Pharmaceutical Creams and their use in wound healing: A Review | |
| US5032400A (en) | Shark liver oil and garlic oil topical analgesic | |
| US11564963B2 (en) | Topical compositions, process of large-scale manufacture, and method of use | |
| US12514895B2 (en) | Topical herbal healing formulation | |
| US20120308670A1 (en) | Topical Medicament for the Treatment of Psoriasis | |
| CN105899221B (en) | Composition for skin based on algae and olive leaf extract | |
| US7262224B2 (en) | Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof | |
| US8383166B2 (en) | Stable hydrophobic topical herbal formulationn | |
| US6200570B1 (en) | Herbal formulation useful as a therapeutic and cosmetic applications for the treatment of general skin disorders | |
| US10426803B2 (en) | Topical medicament for skin and mucosal injuries | |
| US6383499B1 (en) | Topical medicament for the treatment of psoriasis | |
| US20080193552A1 (en) | Topical medicament for skin injuries and disorders | |
| JP2024516248A (en) | Wound Care Composition | |
| EP4153321A1 (en) | Topical compositions, process of large-scale manufacture, and method of use | |
| RU2369377C1 (en) | Phytobalsam insofit for skin regeneration | |
| WO2021257027A1 (en) | An effective composition in healing wounds | |
| WO2004096119A2 (en) | Topical pharmaceutical compositions, methods of manufacture thereof and articles of manufacture containing same | |
| CN115671239B (en) | A kind of anti-inflammatory, anti-swelling, anti-bacterial, anti-itching, anti-crack and repairing frostbite cream and its preparation method | |
| RU2602691C2 (en) | Cosmetic product | |
| CA3082615C (en) | Topical compositions, process of manufacture and method of use | |
| WO2025109346A1 (en) | Topical formulation for wound and burn treatments | |
| KR960015725B1 (en) | Hair Treatment Composition | |
| AU2023203452B1 (en) | Topical formulations | |
| WO2024247342A1 (en) | Ginger component-containing topical agent for reducing pain | |
| EP4618950A1 (en) | Substance mixture for use in the dermal treatment of a skin disease, in particular an oncological hand-foot syndrome, and method for producing the substance mixture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |